Inhalation Sciences receives advanced booking payment for upcoming IRS project in April 2023
A returning US client of Inhalation Sciences AB (ISAB) will pay a 50,000 Euro deposit to book lab time and facilities in April 2023 for an Inhalation Research Services’ R&D project. The total value of the entire project will be confirmed later. The client has chosen ISAB’s high-precision, specially tailored IPL (Isolated Perfused Lung) method for the IRS project.
A mid-size US pharma company that is a returning ISAB client, will make an advanced payment of 50,000 Euro to book the company’s IRS team and IPL facilities for project work in April 2023. The total value of the project will be confirmed later.
The client has chosen ISAB’s IPL (Isolated Perfused Lung) method for the project. Whilst IPL is a well-established experimental model in preclinical pharma studies for both biologics and small molecules, ISAB’s version is specially tailored and designed for aerosols generated by the company’s PreciseInhale® system.
ISAB CEO Manoush Masarrat: “This advanced booking is great news. It underlines the unmet need for full-service providers that can offer SMEs (Small to Medium-sized Enterprises) developing inhaled drugs advanced preclinical technology that can de-risk their development work from day one. We are pleased to welcome back our valued customer.”
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and Dissolv It® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 7 February 2023.
Tags: